Olga Vladimirova Selected Research

Neoplasms (Cancer)

1/2023	Elevated iNOS and 3'-nitrotyrosine in Kaposi's Sarcoma tumors and mouse model.
1/2022	DAXX-ATRX regulation of p53 chromatin binding and DNA damage response.
11/2020	Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism.
10/2019	ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
1/2016	Subtelomeric p53 binding prevents accumulation of DNA damage at human telomeres.
9/2013	Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Olga Vladimirova Research Topics

Disease

6	Neoplasms (Cancer) 01/2023 - 09/2013
2	Latent Infection 01/2021 - 01/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2023
1	Primary Effusion Lymphoma 11/2020
1	Chromosomal Instability (Chromosome Stability) 06/2019
1	Infections 01/2017

Drug/Important Bio-Agent (IBA)

3	ChromatinIBA 01/2022 - 01/2016
2	Histones (Histone)IBA 01/2022 - 10/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2017
1	3-nitrotyrosineIBA 01/2023
1	omega-N-Methylarginine (NG Monomethyl L Arginine)IBA 01/2023
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2023
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2022
1	latency-associated nuclear antigenIBA 01/2021
1	TAK-165IBA 11/2020
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2019
1	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2013

Therapy/Procedure

1	Therapeutics 11/2020